Drug name - Descovy
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| CN1706855A | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN100402539C | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN1291994C | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| CN1443189A | GILEAD SCIENCES INC | Phosphonate Nucleotide Analog Prodrug And Screening And Preparing Method Thereof |
Jul, 2021
(1 year, 2 months ago) | |
| IN200600529P3 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues |
Jul, 2021
(1 year, 2 months ago) | |
| IN241597B | GILEAD SCIENCES INC | Methoxy Phosphonate Nucleotide Prodrug |
Jul, 2021
(1 year, 2 months ago) | |
| IN200300009P3 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| IN208435B | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP2682397B1 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP2682397A1 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP1301519A2 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP1301519B1 | GILEAD SCIENCES INC | Prodrugs Of Phosphonate Nucleotide Analogues And Methods For Selecting And Making Same |
Jul, 2021
(1 year, 2 months ago) | |
| EP2744810B1 | GILEAD SCIENCES INC | Tenofovir Alafenamide Hemifumarate |
Aug, 2032
(9 years from now) | |
| EP2744810A1 | GILEAD SCIENCES INC | Tenofovir Alafenamide Hemifumarate |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7390791
(Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(3 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 120MG;EQ 15MG BASE | TABLET;ORAL | Prescription |
| 200MG;EQ 25MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.